# BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

> **NCT02805023** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioGenCell Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Limb-Threatening Ischemia
- Peripheral Arterial Disease
- Peripheral Vascular Disease

## Interventions

- **BIOLOGICAL:** BGC101 (autologous EnEPC preparation)
- **BIOLOGICAL:** Control medium

## Key facts

- **NCT ID:** NCT02805023
- **Lead sponsor:** BioGenCell Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2017-07
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805023, "BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02805023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*